Summary In vivo models of acquired resistance to the platinum-based agents cisplatin (CDDP), carboplatin (CBDCA), iproplatin (CHIP) In addition to primary resistance, the acquisition of tumour resistance to the platinum-based drugs cisplatin and carboplatin often results in unsuccessful treatment outcome. This is particularly the case for advanced ovarian cancer, where despite initial response rates of the order of 50%, the majority of patients will ultimately succumb to their disease (Ozols, 1991) . Although carboplatin is undoubtedly able to offer patients a more acceptable level of morbidity compared to cisplatin, the results of both randomised and cross-over studies indicate that the two agents are effective against essentially the same population of tumours (Gore et al., 1989; Mangioni et al., 1989; Eisenhauer et al., 1990; Advanced Ovarian Trialists Group, 1991) . Therefore, there remains an unequivocal need to discover and develop additional drugs which possess activity against cisplatin/carboplatin-resistant tumours.
In addition to primary resistance, the acquisition of tumour resistance to the platinum-based drugs cisplatin and carboplatin often results in unsuccessful treatment outcome. This is particularly the case for advanced ovarian cancer, where despite initial response rates of the order of 50%, the majority of patients will ultimately succumb to their disease (Ozols, 1991) . Although carboplatin is undoubtedly able to offer patients a more acceptable level of morbidity compared to cisplatin, the results of both randomised and cross-over studies indicate that the two agents are effective against essentially the same population of tumours (Gore et al., 1989; Mangioni et al., 1989; Eisenhauer et al., 1990; Advanced Ovarian Trialists Group, 1991) . Therefore, there remains an unequivocal need to discover and develop additional drugs which possess activity against cisplatin/carboplatin-resistant tumours.
There is now a general consensus that cisplatin exerts its cytotoxic effects through binding to DNA to produce a variety of cross-links; both intra-and inter-strand (e.g. Roberts et al., 1986 for a review). Studies of platinuminduced tumour resistance have generally utilised in vitro tumour cell line models, both murine (e.g. L1210 ; Burchenal et al., 1977 or P388; Waud et al., 1991) or human tumours such as ovarian (e.g. Behrens et al., 1987) or lung (Hospers et al., 1988) . Typically, pairs of sensitive and cisplatin-acquired resistant variant cell lines have been established where resistance has been generated in vitro by exposure to high concentrations of cisplatin over many months. These investigations indicate that the basis for platinum resistance is often multifocal, involving one or more of decreased accumulation, increased intracellular detoxification (through glutathione or metallothionein) or increased DNA repair (Andrews & Howell, 1990a; McKeage et al., 1991 , for reviews). The clinical relevance of these in vitro based findings, however, is largely untested.
To date, there has been relatively little study of platinum resistance in the in vivo setting, either involving primary human tumour tissue or murine-based tumour models. While some mechanistic studies of drug resistance (e.g. the occurrence of multidrug resistance) have been successfully carried out in patients, the routine usage of primary human tissue can be problematic. Commonly, only a small biopsy from a heterogeneous tumour is available; results may be difficult to interpret due to patient treatment with additional nonplatinum drugs; there is generally not a continual, dependable, supply (especially within patients before and after treatment); and the definition of resistance in the clinical setting is largely subjective. An appropriate alternative, which offers a continual supply of human tumour tissue, might be the use of human tumour xenografts grown in athymic nude mice.
Our platinum-based drug discovery programme is aimed at developing drugs capable of circumventing cisplatin/carboplatin resistance. To assist in this objective, we have established panels of in vitro (Hills et al., 1989) and in vivo (Harrap et al., 1990) human ovarian carcinoma lines. Furthermore, these panels exhibit an excellent in vitro vs in vivo correlation in cisplatin sensitivity/response (Kelland et al., 1992b) . In this study, we report on the establishment of in vivo models of platinum acquired resistance using six human ovarian carcinoma xenografts. Resistance has been generated to cisplatin (three lines), carboplatin (one line), iproplatin (three lines) and tetraplatin (one line) either by treatment in vivo or (for one line) through exposure in vitro and subsequent transfer to mice. We have used these models, including the one pair of lines available both in vitro and in vivo, to determine cross-resistance profiles to these platinum agents.
Materials and methods

Human tumour xenografts
Six parent human ovarian carcinoma tumour lines have been used in this study; HX/110, PXN/87, PXN/94, PXN/95, PXN/100 and PXN/109T/C. Their establishment, characterisation and calibration against cisplatin, carboplatin, iproplatin and tetraplatin has been described previously (Harrap et al., 1990 (Kelland et al., 1992c) .
Tissue storage, karyotyping, histopathology All tumour material was stored between passage under liquid nitrogen. Karyotypic analysis was performed on both parent and resistant sublines by the administration of colcemid (1 mg kg-') to animals for 3 h. Tumours were then excised, chopped, homogenised and cells swollen in hypotonic KCI (0.075 M) for 20 min. Cells were then fixed with ice-cold glacial acetic acid:methanol (1:3), and dropped onto slides. Spreads were air dried and stained with 5% Giemsa for 10 min. Histological sections were prepared by fixing tumours in modified Methacarn and staining sections with haematoxylin and eosin.
Platinum agents
The platinum-containing agents cisplatin (CDDP, Neoplatin, cis-Diamminedichloroplatinum (II)), carboplatin {JM8, CB-DCA, Paraplatin, cis-Diammine-l,l-cyclobutane-dicarboxylato-platinum (II)) and iproplatin (JM9, CHIP, cis-dichlorotrans-dihydroxo-cis bis (isopropylamine) platinum (IV)) were synthesised by and obtained from the Johnson Matthey Technology Centre (Reading, Berkshire). Tetraplatin {Orma-platin, NSC 363812, trans-d,l 1,2-diaminocyclohexane tetrachloroplatinum (IV)) was kindly provided by Dr M. Wolpert-Defilippes (NCI, Bethesda, MD, USA).
Assessment of chemosensitivity
In order to maintain levels of resistance, animals bearing established resistant lines were treated with the maximum tolerated dose (MTD) of the appropriate agent at each passage. Maximum tolerated doses, (CDDP, 8 mg kg-'; CBDCA, 100mgkg-'; CHIP, 60mgkg-1; tetraplatin, 8mg kg-') were administered intraperitoneally (i.p.) in saline; doses were determined from previously described experiments (Harrap et al., 1990; Kelland et al., 1992b) . Following the maintenance dose, at least 10 days were allowed to elapse before tumours were passaged for subsequent chemosensitivity assessment.
Chemosensitivity was then assessed as described previously (Harrap et al., 1990; Kelland et al., 1992b) . Briefly, mice bearing comparably-sized tumours (approximately 8 mm diameter) were randomised into treatment groups (six animals), or control groups (ten animals). Drugs were administered by i.p. injection in saline at the MTD, on day 0 and thereafter, on days 7, 14 and 21. Tumour volumes (V) were then calculated from weekly caliper-derived diameter measurements according to the formula: V = a x b2 x 11/6 (where (a) is the longest diameter and (b) the next longest diameter at right angles to (a), and volumes then normalised to the volume at the start of treatment (day 0).
As previously (Harrap et al., 1990; Kelland et al., 1992b ), experiments were analysed by two methods: (1) 28 day T/C; the ratio of the mean relative tumour volume of treated, to that of control groups on day 28 post-treatment and, for two of the lines, (2) growth delay; the difference in the time taken for control vs treated tumours to double their volume. The 28-day post-treatment time was chosen since it represented an ethically acceptable duration of survival for all untreated control animals. From the growth delay data, specific growth delay values (SGD) (an estimate of the number of volume doubling times by which growth is delayed) have been determined according to published methods (Steel et al., 1983) .
Determination of resistance factors in CHJ/CHJcisR These cell lines were grown in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% heat inactivated (55°C, 30 min) foetal calf serum and 50 1tg ml-' gentamicin, 2.5 fg.ml-' amphotericin B, 2 mM L-glutamine, 10 Ig ml-l insulin and 0.5 jig.ml-' hydrocortisone in 10% C02/90% air as described previously (Kelland et al., 1992c) .
Platinum agents were dissolved as for the xenograft experiments and cytotoxicity assessed following 96 h drug exposure by the sulforhodamine B (SRB) assay as previously described (Mistry et al., 1991) . Resistance factors were determined as ratios of the IC50 values for the pair of cell lines.
Results
A total of eight acquired resistant lines, were successfully established. Lines have been assigned according to the agent used to generate resistance; C = cisplatin (PXN/87C, PXN/ 95C, PXN/109T/CC), P = carboplatin (Paraplatin) (HX/ 1 lOP), I = iproplatin (PXN/871, PXN/941, PXN/951) and T = tetraplatin (PXN/1OOT). Seven of these were established by treatment of tumours in vivo while PXN/109T/CC was derived from the companion cell line, CHlcisR. The doses used and the times taken to generate resistance are shown in Table I . The average total time for resistance to be established in vivo was 88 weeks; a similar time (70 weeks) was observed for the in vitro derived CHlcisR (corresponding to the PXN/109T/CC) cell line. It should be noted that for HX/llOP and PXN/87C, the doses used to establish resistance were a little higher than our above quoted MTD values (while, for tetraplatin, a lower dose was used). Values (in days ± s.d.) were HX/l 10, 6.6 ± 4 and HX/1 lOP, 7.9 ± 4.8; PXN109T/C, 8.6 ± 1.2 and PXN109T/CC, 7.2 ± 0.2; PXN/95, 17.7 ± 6.6 and PXN95C, 14.5 ± 0.2; PXN/87, 12.1 ± 9.3 and PXN/871, 12 + 1.1. Three appeared to grow somewhat faster: PXN/941 7.5 ± 2.5 days compared to 17.5 ± 8.2 days for the parent line; PXN/951 8.5 ± 0.2 days compared to 17.7 ± 6.6 days for the parent line and PXN/ lOOT 4.8 ± 1.8 days compared to 7.2 ± 3.2 days for the parent line. One line, PXN/87C (24.2 ± 6.1 days) grew more slowly than the parent (12.1 ± 9.3 days). 0.0 _1-a marked sensitivity (i.e. T/C <0.1) to the DACH-platinum (IV) complex, tetraplatin. To date, it has not proven possible to generate resistance to cisplatin or carboplatin in this highly platinum-sensitive tumour (due primarily to druginduced complete tumour regression). Where resistance has been derived to tetraplatin (PXN/1OOT) some degree of sensitivity was retained by cisplatin (T/C of 0.04).
Since at least a 6 week gap occurred between the maintenance dose of platinum drug and chemosensitivity testing (i.e. while the tumour was transplanted into mice and the tumours grew to 8-10 mm diameter) it is clear that resistance is stable for at least 2 months. However, we have not, as yet, conducted studies into the longer-term stability of the resistance in the absence of maintenance doses. Figure 3b . The four lines with acquired resistance to the platinum (II) agents cisplatin (PXN/87C, PXN/95C and PXN/109T/CC) and carboplatin (HX/l lOP) showed a general cross-resistance to the other agents studied (Figures 1-3 (Gore et al., 1989; Eisenhauer et al., 1990) and cisplatin followed by iproplatin (Sessa et al., 1988; Weiss et al., 1991) . These cross-over studies strongly suggest that all three agents essentially share cross-resistance with each other. Our data using four xenografted lines with derived resistance to cisplatin and carboplatin are reminiscent of these clinical observations; cross-resistance being exhibited to cisplatin/carboplatin and iproplatin.
Other reports of in vivo tumour models of cisplatin acquired resistance are mainly murine-based (Ferrari et al., 1989; Goddard et al., 1991) , rat (Zeller et al., 1991) , and two involving human ovarian tumours (A2780, Rose & Basler, 1990, and 2008; Andrews et al., 1990b) . In common with our findings, the A2780/A278OcDDP models, where acquired resistance was originally developed in vitro (Behrens et al., 1987) , also showed cross-resistance to carboplatin, iproplatin and tetraplatin (Rose & Basler, 1990) . In addition, crossresistance to these agents has been observed in other murinebased cisplatin resistant tumours; the M5076 reticular cell sarcoma (Ferrari et al., 1989) , and the ADJ/PC6 plasmacytoma (Goddard et al., 1991) .
The PXN/109T/C and cisplatin-resistant pair of xenografts and the companion CHI and CHlcisR pair of in vitro cell lines exhibited similar patterns of cross-resistance to the other platinum agents studied. We have also observed a strong positive correlation in cisplatin response between eight in vitro 'parent' human ovarian carcinoma cell lines and companion xenografts (Kelland et al., 1992b) . As previously reported, CHlcisR is approximately 6-fold resistant to cisplatin compared to CHI (Kelland et al.,1992c (Kelland et al., 1992c) . This is the first study we are aware of where resistance has 0) been generated in vivo to the platinum (IV) agents iproplatin and tetraplatin. There was some evidence of a different pattern of cross-resistance being obtained compared to that observed for the cisplatin/carboplatin resistant lines. In particular, in one iproplatin-resistant line (PXN/951), cisplatin and carboplatin circumvented resistance; exhibiting a similar level of response to that observed for the parent line. In another tumour, PXN87I, cisplatin retained some activity. In addition to the differences in cross-resistant data, the platinum (IV) drugs also appeared to induce some differences in tumour histology compared to cisplatin and carboplatin. This was most notable for the PXN/87 and PXN/95 tumours where resistance to cisplatin induced no change in histological appearance whereas resistance to iproplatin induced changes consistent with increased tumour differentiation.
Tetraplatin is currently in phase I clinical trial (Christian et al., 1991) . It was selected for clinical trial based largely on its ability to circumvent acquired cisplatin resistance in murine L1210 leukaemia cells, both in vitro and in vivo (Burchenal et al., 1977) . In our previous studies using two murine tumour models with acquired cisplatin resistance, the L1210 leukaemia and the ADJ/PC6 plasmacytoma, tetraplatin was even more active in the resistant L1210 than in the parent tumour (thus confirming the published studies) but shared crossresistance with carboplatin and iproplatin in the ADJ/PC6 (Goddard et al., 1991) . In the panel of human ovarian xenografts used herein, tetraplatin was markedly active (T/C of <0.1) against only the highly platinum-sensitive PXN/100 line.
In summary, similarly to clinical cross-over studies, we have observed shared cross-resistance between cisplatin, carboplatin and iproplatin in four cisplatin or carboplatinacquired resistant tumours. There was some evidence that generation of resistance to the platinum (IV) agents iproplatin (and to a lesser extent, tetraplatin) might induce a different pattern of cross-resistance. Cisplatin appeared to retain some activity in three of four such tumours. These in vivo models of acquired platinum reistance provide a useful addition to our repository of preclinical models (both human and murine) to be used for the discovery of novel more broad-spectrum platinum-based anticancer drugs. In particular, they complement our recently described in vitro models of acquired resistance (Kelland et al., 1992a,b) and companion in vitro and in vivo human ovarian carcinoma models of intrinsic cisplatin resistance (Hills et al., 1989; Harrap et al., 1990; Kelland et al., 1992a,b) . Furthermore, these models allow the opportunity to investigate further the biochemical mechanisms responsible for the resistance of tumours to cisplatin and whether, as has recently been suggested for the murine EMT-6 tumour (Teicher et al., 1990) , some mechanisms only operate in vivo.
